LENSAR Inc reported QQ2 2024 revenue of $12.64 million, up 5.2% year-over-year and 19.3% sequentially, underscoring modest top-line momentum in a mature cataract laser market. The gross margin stood at 52.1%, generating gross profit of $6.58 million, indicating a solid product margin despite ongoing operating pressures. However, the quarter delivered a substantial net loss of $9.04 million and an EBITDA loss of $0.65 million, with total other income/expenses contributing -$7.49 million. The negative bottom-line was driven primarily by non-operating items, masking a relatively healthy gross margin and a still-meaningful installed-base opportunity. Operating cash flow was negative at $(3.78) million, contributing to a free cash flow decline of $(3.89) million for QQ2 2024. Cash and equivalents (including short-term investments) totaled $14.21 million against total liabilities of $23.98 million, yielding a net debt position of $(6.25) million and a current ratio of 3.88x, indicative of liquidity cushion but with balance-sheet pressures from high non-cash and non-operating charges. Management commentary (where available) and non-operating drivers warrant close monitoring as the company navigates a high-OPEX environment while pursuing additional revenue catalysts such as instrument uptake and service-related revenue.